Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about LKFT, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Anti-Tumor Necrosis Factor Alpha Drug (Product) | Rheumatoid Arthritis | Phase 4 · NCT04985435 | Recruiting |
| Filgotinib | Rheumatoid Arthritis | Phase 4 · NCT04985435 | Recruiting |
| Methotrexate | Rheumatoid Arthritis | Phase 3 · NCT02889796 | Completed |
| Ziritaxestat | Idiopathic Pulmonary Fibrosis | Phase 3 · NCT03733444 | Terminated |
| GLPG3970 | Primary Sjögren Syndrome | Phase 2 · NCT04700280 | Terminated |
| Cadefrecitinib | Dermatomyositis | Phase 2 · NCT05695950 | Completed |
| GLPG1205 | Idiopathic Pulmonary Fibrosis | Phase 2 · NCT03725852 | Completed |
| GLPG1972 | Osteoarthritis | Phase 2 · NCT03595618 | Completed |
| GLPG2737 | Autosomal Dominant Polycystic Kidney Disease | Phase 2 · NCT04578548 | Terminated |
| GLPG4399 oral suspension | Healthy | Phase 1 · NCT04653467 | Completed |
| GLPG4716 | Healthy | Phase 1 · NCT04971746 | Completed |
| OM336 | Sjogrens Disease | Phase 1 · NCT07229144 | Recruiting |
| Pravastatin | Rheumatoid Arthritis | Phase 1 · NCT04608344 | Completed |
| Rosuvastatin | Rheumatoid Arthritis | Phase 1 · NCT04608344 | Completed |
| [14]GLPG3970 oral solution | Healthy | Phase 1 · NCT04907149 | Completed |
| GLPG4399 capsules | Healthy | Phase 1 · NCT04653467 | Completed |
Also used in these trials (approved or third-party drugs, not LKFT's own candidates): Adalimumab, Prednisone, Itraconazole, Midazolam Hydrochloride, Sulfasalazine, Nintedanib, Pirfenidone.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
LKFT holds $2.2B in cash and short-term investments and burns about $56.7M/quarter from operations, an estimated runway of 118.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LKFT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 5%+ holder (13D) | 20,981,010 | 31.84% | 2025-01-07 |
| EcoR1 Capital, LLC | Institution (13G, 5%+) | 8,714,522 | 13.22% | 2025-07-24 |
| Madison Avenue International LP | 5%+ holder (13G) | 3,606,203 | 5.47% | 2026-06-15 |
Share count 65,897,071 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LKFT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →